Jennifer A. Doudna
CIK: 0001739090
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Cathie Wood's ARKG adds Scribe Therapeutics to its biotech holdings. ARK Genomic Revolution ETF (ARKG) increased its position in Scribe Therapeutics, as reported by Yahoo and Benzinga. The addition places Scribe among four biotech names that the fund has recently loaded up on. The stock also appeared in a list of health‑care shares moving in the pre‑market session. This news brings additional attention to the company while the stock shows modest momentum on the chart.
Transaction History
| TEM | ▼ Sell | Open Market | 676 | $44K | 9/1/2026 | View on chart |
| SCTX | ▼ Sell | Other | 12,511 | — | 7/27/2026 | View on chart |
| TEM | ▼ Sell | Open Market | 2,673 | $147K | 6/25/2026 | View on chart |
| TEM | ▲ Buy | Grant | 5,913 | $0 | 5/21/2026 | View on chart |
| TEM | ▼ Sell | Open Market | 1,250 | $75K | 1/2/2026 | View on chart |
| TEM | ▼ Sell | Open Market | 676 | $51K | 12/1/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 1,926 | $138K | 11/11/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 625 | $39K | 7/1/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 558 | $31K | 6/2/2025 | View on chart |
| TEM | ▲ Buy | Grant | 1,997 | $0 | 5/20/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 625 | $30K | 4/1/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 2,006 | $94K | 3/17/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 2,046 | $98K | 3/17/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 1,214 | $59K | 3/17/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 3,142 | $157K | 3/17/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 900 | $46K | 3/17/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 338 | $19K | 3/3/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 1,320 | $119K | 2/14/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 1,183 | $49K | 12/11/2024 | View on chart |
| TEM | ▲ Buy | Grant | 38,514 | $0 | 6/13/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Tempus AI Expands Collaborations, Canaccord Raises Target to $95
Tempus AI is expanding its strategic collaborations to support future growth. Canaccord Genuity recently raised its price target for the stock to $95. This development occurs as the company prepares to report its third-quarter financial results on November 2.
Tempus AI Expands Collaborations, Canaccord Raises Target to $95. Tempus AI is expanding its strategic collaborations to support future growth. Canaccord Genuity recently raised its price target for the stock to $95. This development occurs as the company prepares to report its third-quarter financial results on November 2.